公司资料
BridgeBio 股价、新闻与催化剂
- 股票代码:
- BBIO
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
81.50 USD (-1.74%)
收盘价
最后更新: 2026年8月21日
12.5B USD
市值
股价为何变动
The latest monitored company update is “BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026.” The corresponding closing-price reaction is not yet available.
公司概览
Genetically Defined Diseases
BridgeBio Pharma develops medicines for genetic diseases and genetically driven cancers. Its decentralized portfolio model creates focused teams around individual disease programs.
Attruby
Attruby, or acoramidis, is an oral transthyretin stabilizer approved for transthyretin amyloid cardiomyopathy. It anchors BridgeBio's commercial rare-cardiovascular franchise.
BBP-418
BBP-418 is an oral substrate-supplementation therapy under FDA review for limb-girdle muscular dystrophy type 2I/R9.
Encaleret
Encaleret is an oral calcium-sensing-receptor antagonist being prepared for regulatory submission in autosomal dominant hypocalcemia type 1.
Infigratinib
Low-dose oral infigratinib targets FGFR3 signaling in achondroplasia and is advancing toward an NDA based on late-stage clinical development.
未来催化剂
- NDA submission for encaleret in autosomal dominant hypocalcemia type 1 in the first half of 2026.
- NDA submission for oral infigratinib in achondroplasia in the third quarter of 2026.
- FDA review milestones for the submitted BBP-418 application, including a potential Priority Review decision.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。